Search the Newsreel

DRMA Stock Draws Traders As Dermata Pivots To Skincare Launch

Dermata Therapeutics (DRMA) stock is seeing increased trading activity and positive sentiment due to its strategic pivot towards a direct-to-consumer skincare market. The company is set to launch "Tome Foundational Treatment," its first skincare product utilizing Bioneedle technology, on August 25, 2026. This move …

Dermata Therapeutics Shares Jump 28.73% Pre-Market - Dermata Therapeutics (NASDAQ:DRMA)

Dermata Therapeutics Reports Q2 2026 Results Ahead Of First Product Launch; Stock Up

(RTTNews) - Dermata Therapeutics, Inc. (DRMA) announced financial results for the second quarter ended June 30, 2026, alongside a corporate update highlighting its transition into a commercial-stage skincare company. The San Diego-based firm is preparing to launch its first direct-to-consumer product, Tome Foundational Treatment, …

DERMATA THERAPEUTICS ($DRMA) Releases Q2 2026 Earnings, Stock Rises

DERMATA THERAPEUTICS ($DRMA) released its Q2 2026 earnings, reporting -$0.74 per share, missing estimates by $0.18, with revenue matching expectations at $0. Despite missing earnings estimates, the stock price rose by 43.66% since market close. The article also details recent insider trading activity, including …

Trending Stocks Today | Dermata Therapeutics Soars 35.18% Post-Market

Dermata Therapeutics (DRMA) experienced a significant post-market surge of 35.18%. This jump follows the company's announcement of positive topline data from its Phase 2b trial for DMT310 in treating moderate-to-severe rosacea. The results showed statistically significant improvements in inflammatory lesion count, erythema, and Global …

12 Health Care Stocks Moving In Tuesday's After-Market Session

This article details the performance of 12 health care stocks during Tuesday's after-market session, highlighting both gainers and losers. Several companies, including Dermata Therapeutics and CytoSorbents, saw their stock prices increase, often coinciding with recent Q2 earnings reports. Conversely, stocks like Edap TMS and …

DRMA Financials: Income Statement, Balance Sheet & Cash Flow

Dermata Therapeutics (DRMA) faces going concern warning amid higher losses and cash burn

Dermata's Tome Skincare Product Is Designed for Once-Weekly Use

Dermata Therapeutics (NASDAQ:DRMA) announced its Q2 2026 financial results, revealing a strategic pivot to a direct-to-consumer skincare model. The company is set to launch its first product, Tome Foundational Treatment, on August 25, 2026, with manufacturing and packaging complete. Despite a net loss of …

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics (NASDAQ: DRMA) announced its financial results for the second quarter of 2026 and provided a corporate update, highlighting its transition to a commercial-stage, direct-to-consumer skincare company. The company expects to launch its first commercial product, Tome™ Foundational Treatment, on August 25, 2026, …

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Dermata Therapeutics (NASDAQ:DRMA) announced that its first direct-to-consumer skincare product, Tome Foundational Treatment, will launch on August 25, 2026. This product, featuring proprietary Bioneedle™ technology, marks Dermata's strategic shift to a consumer-focused skincare company, offering a professional-grade skin renewal treatment for at-home use. The …

Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview

Dermata Therapeutics Inc (DRMA) is projected to report a loss of 55 cents per share, according to an earnings preview. The article, sourced from Reuters, indicates that this financial forecast is available through TradingView News.

Dermata to launch first consumer skincare product Aug. 25 By Investing.com

Dermata Therapeutics (NASDAQ:DRMA) announced the upcoming launch of its first direct-to-consumer skincare product, Tome Foundational Treatment, on August 25, 2026. This launch marks a strategic shift for the company from developing prescription dermatologic products to focusing on consumer skincare. The Tome Foundational Treatment is …

Dermata’s First Consumer Brand Wants to Function as ‘Microneedling Lite’

Dermata Therapeutics is launching its first consumer skincare brand, Tome, which features a "microneedling lite" weekly treatment. The product, priced at $178 for four treatments, uses Spongilla lacustris spicules to accelerate cell turnover and address various skin concerns. Tome plans to target experienced skincare …

DRMA strengthens EV ecosystem, targets sustainable growth

Dermata Therapeutics, Inc. Revenue Breakdown – NASDAQ:DRMA

This article provides a financial overview of Dermata Therapeutics, Inc. (NASDAQ:DRMA) on TradingView. It indicates that the market was closed with no trades. The content also lists various financial and analytical tools available on the platform, alongside information about the company and community features.

DRMA posts IDR 282.9 billion net profit in H1 2026, up 17.8%

PT Dharma Polimetal Tbk Reports Earnings Results for the Half Year Ended June 30, 2026

DRMA|Dermata Therapeutics Inc|Price:1.290|Chg%:-0.030

This article provides a detailed explanation of TradingKey's stock scoring methodology for Dermata Therapeutics Inc (DRMA), covering financial health, company valuation, earnings forecasts, price momentum, institutional confidence, and risk management. It notes that a stock score is not yet available for DRMA due to …

Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Dermata Therapeutics Inc (DRMA), including its stock price, market cap, and links to financial data and analysis tools on TradingKey. It notes that key valuation metrics like P/E, P/B, and P/CF ratios have not yet been disclosed …

TradingKey

This article presents the quarterly and annual cash flow statements for Dermata Therapeutics Inc (DRMA), detailing operating, investing, and financing cash flows from FY2020Q1 to FY2026Q1. It provides a financial summary of the company's performance, including net income from continuing operations and changes in …

Dermata Therapeutics, Inc. Revenue Breakdown – BOATS:DRMAW

This article provides a financial overview of Dermata Therapeutics, Inc. (DRMAW) on TradingView, focusing on its revenue breakdown. It indicates that no trade data was available at the time of publication, suggesting the market was closed or trading was halted. The page acts as …

Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW

This article provides the "Price to earnings forward" data for Dermata Therapeutics, Inc. (NASDAQ:DRMAW). It indicates that the market is currently closed, with no trades, and the data is sourced from ICE Data Services and FactSet Research Systems Inc.

PT Dharma Polimetal Tbk Actuals & Estimates (IDX:DRMA)

Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch

Dermata Therapeutics Strategically Pivots with New Skincare Launch

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ

DRMA boss Irianto Santoso: DRMA's first quarter net profit grew 6.7%

Dharma Polimetal Optimistic To Maintain Performance In The Fourth Quarter Of 2024, Aiming For Automotive Opportunities And EVs In 2025

Dharma Polimetal exports automotive components to the United States

Good News From Dharma Polimetal, TP Rachmat Conglomerate Owned Company That Promises To Share Dividends After IPO